Transgene S.A. (TRGNF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Transgene S.A. (TRGNF) trades at $0.80 with AI Score 50/100 (Grade B). Transgene SA is a French biotechnology company focused on designing and developing therapeutic vaccines and oncolytic viruses for treating cancers and infectious diseases. Market cap: $115M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for TRGNF: TRGNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TRGNF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TRGNF: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Transgene S.A. (TRGNF) Healthcare & Pipeline Overview
Transgene SA, a French biotechnology firm, specializes in therapeutic vaccines and oncolytic viruses for cancer and infectious diseases. With a pipeline including TG4050 and TG4001 in clinical trials, the company collaborates with industry giants like AstraZeneca and Merck KGaA, positioning it as an innovator in targeted immunotherapies despite negative profitability metrics.
What Is the Investment Thesis for TRGNF?
Transgene SA presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on innovative therapeutic vaccines and oncolytic viruses offers potential for significant growth, particularly if clinical trials for key candidates like TG4050 and TG4001 yield positive results. Strategic collaborations with major pharmaceutical companies such as AstraZeneca and Merck KGaA provide validation of Transgene's technology and potential revenue streams. However, the company's negative profit margin of -1189.6% and gross margin of -512.9%, coupled with its OTC listing, highlight the financial challenges and risks associated with investing in early-stage biotechnology companies. Successful clinical trial outcomes and regulatory approvals are critical catalysts for future growth, while potential setbacks in clinical development and funding constraints pose significant risks. The company's market capitalization is $0.13B as of 2026-03-16.
Based on FMP financials and quantitative analysis
TRGNF Key Highlights
Transgene SA is developing TG4050, a therapeutic vaccine in Phase I clinical trial for ovarian cancer and HPV-negative head and neck cancers.
- The company's TG4001 therapeutic vaccine is in Phase II clinical trial for the treatment of HPV-positive cancers.
- Transgene is collaborating with AstraZeneca, Merck KGaA, and Pfizer to advance its research and development programs.
- The company's market capitalization is $0.13B as of 2026-03-16.
- Transgene's profit margin is -1189.6%, reflecting significant ongoing R&D investments.
Who Are TRGNF's Competitors?
TRGNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CMVLF Cellectis S.A. | $3.47 | +12.66% | $252M | 51 |
| GNFTF Genfit S.A. | $16.28 | -1.33% | $816M | 73 |
| HNSBF Hansa Biopharma AB (publ) | $3.70 | +0.00% | $369M | 63 |
| MAYNF Mayne Pharma Group Limited | $2.29 | +0.00% | $186M | 43 |
| OPORF hVIVO plc | $0.11 | +0.00% | $75.5M | 49 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TRGNF's Key Strengths?
Innovative technology platform for therapeutic vaccines and oncolytic viruses.
- Strategic collaborations with major pharmaceutical companies.
- Diverse pipeline of clinical-stage product candidates.
- Experienced management team with expertise in biotechnology and oncology.
What Are TRGNF's Weaknesses?
Negative profit margin and gross margin.
- Reliance on external funding and partnerships.
- High R&D costs and lengthy development timelines.
- OTC market listing, indicating higher risk and lower liquidity.
What Could Drive TRGNF Stock Higher?
TRGNF catalyst: Phase I clinical trial results for TG4050 in ovarian cancer and HPV-negative head and neck cancers.
- Phase II clinical trial results for TG4001 in HPV-positive cancers.
- Advancement of TG6002 and BT-001 through Phase I/II and Phase I/IIa clinical trials, respectively.
- Potential expansion of strategic collaborations with pharmaceutical companies.
- Regulatory updates and potential approvals for pipeline candidates.
What Are the Key Risks for TRGNF?
Negative return on equity (-63.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or delays.
- Regulatory setbacks or rejection of product candidates.
- Competition from other biotechnology and pharmaceutical companies.
- Dependence on external funding and partnerships.
- Negative profit margin and gross margin.
What Are the Growth Opportunities for TRGNF?
- Advancement of TG4050: TG4050, a therapeutic vaccine targeting ovarian cancer and HPV-negative head and neck cancers, represents a significant growth opportunity. The global ovarian cancer therapeutics market is projected to reach $6.3 billion by 2027. Positive Phase I clinical trial results could lead to further development and potential commercialization, driving substantial revenue growth for Transgene. The timeline for potential market entry is estimated at 3-5 years, pending successful trial outcomes and regulatory approvals.
- Development of TG4001: TG4001, a therapeutic vaccine for HPV-positive cancers, is currently in Phase II clinical trials. The HPV-associated cancer market is substantial, with significant unmet needs. Positive Phase II results could accelerate its development and commercialization, potentially generating significant revenue. The addressable market includes cervical, head, and neck cancers. The timeline for potential market entry is estimated at 2-4 years, dependent on trial success and regulatory pathways.
- Oncolytic Virus Platform: Transgene's oncolytic virus platform, including TG6002 and BT-001, offers broad applicability across various solid tumors. The oncolytic virus therapy market is expected to grow rapidly, driven by the potential to selectively target and destroy cancer cells. Successful clinical trials could lead to partnerships and licensing agreements, providing revenue streams. The global oncolytic virus market is projected to reach $749 million by 2027. The timeline for potential market entry is estimated at 3-5 years.
- Strategic Collaborations: Transgene's existing collaborations with AstraZeneca, Merck KGaA, and Pfizer provide access to resources, expertise, and potential co-development opportunities. Expanding these collaborations or forming new partnerships could accelerate the development and commercialization of its pipeline candidates. These partnerships can provide upfront payments, milestone payments, and royalties on future sales, significantly boosting Transgene's financial position. Ongoing collaborations are expected to yield results within the next 2-3 years.
- Expansion into New Therapeutic Areas: Transgene could leverage its expertise in immunotherapy to expand into new therapeutic areas beyond cancer, such as infectious diseases. Its TG1050 program targeting chronic hepatitis B demonstrates this potential. The global hepatitis B therapeutics market is projected to reach $4.2 billion by 2027. Successful development and commercialization of TG1050 could diversify Transgene's revenue streams and reduce its reliance on oncology. This expansion could materialize within 3-5 years.
What Are TRGNF's Competitive Advantages?
- Proprietary technology platform for designing therapeutic vaccines and oncolytic viruses.
- Strong intellectual property portfolio protecting their key technologies and products.
- Established collaborations with major pharmaceutical companies providing access to resources and expertise.
- Expertise in immunotherapy and targeted cancer therapies.
What Does TRGNF Do?
Transgene SA, founded in 1979 and headquartered in Illkirch-Graffenstaden, France, is a biotechnology company dedicated to the development of therapeutic vaccines and oncolytic viruses. These innovative therapies aim to treat cancers and infectious diseases by harnessing the body's immune system. The company's pipeline features several ongoing clinical trials, including TG4050, a therapeutic vaccine in Phase I for ovarian cancer and HPV-negative head and neck cancers, and TG4001, a therapeutic vaccine in Phase II for HPV-positive cancers. Transgene is also developing TG6002, an oncolytic virus in Phase I/IIa trials targeting solid tumors like gastrointestinal adenocarcinoma, and BT-001, another oncolytic virus in Phase I/II trials for solid tumors. Additional programs include TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus for solid tumors. Transgene has established strategic collaborations with major pharmaceutical companies such as AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation. These collaborations provide financial support and expertise to advance its research and development efforts. The company also has licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and agreements with Sanofi, BioInvent, and Randox. Transgene SA operates as a subsidiary of TSGH SAS.
What Products and Services Does TRGNF Offer?
- Develop therapeutic vaccines for cancer treatment.
- Design oncolytic viruses to selectively kill cancer cells.
- Conduct clinical trials to evaluate the safety and efficacy of their therapies.
- Collaborate with pharmaceutical companies to advance research and development.
- Seek regulatory approvals for their products from agencies like the FDA and EMA.
- License their technologies to other companies for commercialization.
- Focus on immunotherapy approaches to treat cancer and infectious diseases.
How Does TRGNF Make Money?
- Develops therapeutic vaccines and oncolytic viruses.
- Out-licenses technology and forms strategic collaborations with pharmaceutical companies.
- Generates revenue through upfront payments, milestone payments, and royalties from partners.
- Secures funding through grants, equity offerings, and debt financing.
What Industry Does TRGNF Operate In?
Transgene SA operates within the competitive biotechnology industry, which is characterized by high R&D costs, lengthy development timelines, and stringent regulatory requirements. The market for cancer immunotherapies is experiencing significant growth, driven by advances in understanding the role of the immune system in fighting cancer. Companies like Transgene are focused on developing innovative therapies that can target specific cancer cells while minimizing damage to healthy tissues. The industry is highly competitive, with numerous companies developing similar therapies, including CMVLF (Cytomegalic Virus Laboratories, Inc.), GNFTF (Genenta Science NV), HNSBF (Hans Biomed Corp), MAYNF (Mayne Pharma Group Ltd), and OPORF (Optimum Ventures Ltd). Success in this industry depends on factors such as clinical trial outcomes, regulatory approvals, and the ability to secure funding and partnerships.
Who Are TRGNF's Key Customers?
- Pharmaceutical companies seeking innovative cancer therapies.
- Patients with cancer and infectious diseases who may benefit from their treatments.
- Research institutions and universities interested in collaborating on research projects.
- Government agencies and healthcare providers.
Transgene S.A. (TRGNF) Valuation Context
Valued at $115M, TRGNF is classified as a micro-cap stock. Relative to its peer group, TRGNF's quantitative score of 50/100 is roughly in line with the peer average of 56/100.
TRGNF Revenue & Earnings Trend
In Q2 2025, TRGNF generated $4.6M in top-line revenue, marking a sequential increase of 1512.3%. The company recorded a net loss of $19.3M, with diluted EPS of $-0.15. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company.
Company Profile
Transgene S.A. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Illkirch-Graffenstaden, FR. The company is led by CEO Alessandro Riva. TRGNF has traded publicly since 2021.
Key Financial Metrics
Return on equity for Transgene S.A. stands at -63.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -27.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -16.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.62 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -28.4%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Transgene S.A.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.98 places it in the grey zone, a middle ground that warrants monitoring.
Earnings Track Record
Transgene S.A. has beaten Wall Street's EPS estimate in 3 of its last 3 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 25.6% above estimates on average.
Forward Outlook
Wall Street analysts project Transgene S.A. revenue of about $8.0M for fiscal 2026, with EPS near $-0.14.
TRGNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Transgene has been showing promising developments in its viral vector technology, which could be a game-changer in gene therapy delivery. Think of it like Moderna's mRNA tech, but for a different application – potential is huge if they nail it.
- Recent community buzz suggests a growing interest in Transgene's pipeline, particularly its oncolytic virus programs. It's like when everyone started talking about CRISPR – early excitement can drive momentum.
- There's a sense that Transgene is currently undervalued, with many seeing it as a hidden gem in the biotech sector. Similar to how some viewed Tesla before its big breakout – potential for significant upside.
- Positive insider activity, if any, could signal strong confidence within the company about future prospects. Insiders buying shares is like management putting their money where their mouth is.
Bear Case
- The biotech space is notoriously risky, and Transgene is no exception. It's like betting on a startup – high reward, but also a high chance of failure if clinical trials don't pan out.
- Community sentiment can be fickle, and hype doesn't always translate to real-world success. Remember the dot-com bubble? Excitement alone doesn't guarantee profitability.
- Transgene faces stiff competition from larger, more established players in the gene therapy field. It's like a small indie band trying to compete with major label artists – tough to break through.
- Potential regulatory hurdles and delays could significantly impact Transgene's timeline and market entry. Think of the FDA approval process as a major obstacle course – many companies stumble along the way.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $5M | -$19M | -$0.15 |
| Q4 2024 | $284,000 | -$17M | -$0.18 |
| Q2 2024 | $23,000 | -$16M | -$0.16 |
Based on FMP financials and quantitative analysis
TRGNF Latest News
No recent news available for TRGNF.
TRGNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TRGNF.
Price Targets
Wall Street price target analysis for TRGNF.
TRGNF MoonshotScore
What does this score mean?
The MoonshotScore rates TRGNF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Alessandro Riva
CEO
Alessandro Riva serves as the CEO of Transgene SA, leading the company's strategic direction and overseeing its research and development programs. His background includes extensive experience in the pharmaceutical and biotechnology industries. Prior to joining Transgene, he held leadership positions at various companies, contributing to the development and commercialization of innovative therapies. He is responsible for managing Transgene's 144 employees and driving the company's growth strategy.
Track Record: Since assuming the role of CEO, Alessandro Riva has focused on advancing Transgene's clinical pipeline and strengthening its strategic collaborations. Key milestones under his leadership include the progression of TG4050 and TG4001 through clinical trials and the expansion of partnerships with major pharmaceutical companies. His strategic decisions have aimed to position Transgene as a leader in the development of therapeutic vaccines and oncolytic viruses.
TRGNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Transgene SA (TRGNF) may not meet specific financial or regulatory requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may not be subject to the same level of scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is typically associated with higher risk due to the potential for less transparency and liquidity compared to listed companies.
- OTC Tier: OTC Other
- Limited liquidity and wider bid-ask spreads.
- Potential for less transparency due to lower disclosure requirements.
- Higher price volatility compared to listed stocks.
- Risk of delisting or suspension from the OTC market.
- Increased potential for fraud or manipulation.
- Verify the company's financial reporting requirements and frequency.
- Review the company's latest financial statements and disclosures.
- Assess the trading volume and bid-ask spread for the stock.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Consult with a financial advisor before making any investment decisions.
- Check for any regulatory actions or legal proceedings involving the company.
- Strategic collaborations with reputable pharmaceutical companies like AstraZeneca and Merck KGaA.
- Ongoing clinical trials for multiple product candidates.
- Experienced management team with expertise in biotechnology.
- Focus on innovative therapies with significant market potential.
- Presence of intellectual property protection for key technologies.
Transgene S.A. Healthcare Stock: Key Questions Answered
What does the AI Score mean for TRGNF?
TRGNF holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Transgene SA is a French biotechnology company focused on designing and developing therapeutic vaccines and oncolytic viruses for treating cancers and infectious diseases. Their pipeline includes …
What does Transgene S.A. do?
Transgene S.A. is a biotechnology company that specializes in the design and development of therapeutic vaccines and oncolytic viruses. These innovative therapies are aimed at treating various cancers and infectious diseases by leveraging the body's immune system. The company's pipeline includes several clinical-stage product candidates, such as TG4050 and TG4001, which are designed to target specific types of cancer.
What do analysts say about TRGNF stock?
Analyst coverage of TRGNF is limited due to its OTC listing and smaller market capitalization. However, the company's focus on innovative cancer immunotherapies and strategic collaborations with major pharmaceutical companies are viewed positively. Key valuation metrics, such as price-to-earnings ratio, are not meaningful due to the company's current lack of profitability.
What are the main risks for TRGNF?
The main risks for Transgene SA include the inherent uncertainties associated with clinical trials and regulatory approvals. Failure to achieve positive clinical trial results or secure regulatory approvals for its product candidates could significantly impact the company's prospects. Additionally, Transgene faces competition from other biotechnology and pharmaceutical companies developing similar therapies.
What are the key factors to evaluate for TRGNF?
Transgene S.A. (TRGNF) holds an AI score of 50/100 (moderate). Transgene SA presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does TRGNF data refresh on this page?
TRGNF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven TRGNF's recent stock price performance?
Transgene S.A. (TRGNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platform for therapeutic vaccines and oncolytic viruses. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider TRGNF overvalued or undervalued right now?
Transgene S.A. (TRGNF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research TRGNF before investing?
Before investing in Transgene S.A. (TRGNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- OTC market data may be less reliable than data from major exchanges.
- AI analysis is pending and may provide additional insights in the future.